BSE Live
Jun 02, 16:01Prev. Close
639.75
Open Price
641.80
Bid Price (Qty.)
632.95 (1)
Offer Price (Qty.)
641.50 (23)
NSE Live
Jun 02, 15:47Prev. Close
640.55
Open Price
634.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
Half Yearly Results of Eris Lifesciences (in Rs. Cr.) | Mar '23 | Sep '22 | Mar '22 | Sep '21 | Mar '21 | |
Net Sales/Income from operations | 635.11 | 672.01 | 577.34 | 628.96 | 554.35 | |
Other Operating Income | 11.48 | 12.12 | 9.44 | -- | -10.37 | |
Total Income From Operations | 646.60 | 684.13 | 586.77 | 628.96 | 543.98 | |
EXPENDITURE | ||||||
Consumption of Raw Materials | 50.62 | 63.51 | 63.22 | 54.35 | 44.23 | |
Purchase of Traded Goods | 50.26 | 63.49 | 44.23 | 35.35 | 57.24 | |
Increase/Decrease in Stocks | 5.87 | 2.63 | -5.23 | 7.72 | -0.83 | |
Power & Fuel | -- | -- | -- | -- | -- | |
Employees Cost | 122.38 | 130.14 | 107.87 | 114.31 | 100.29 | |
Depreciation | 33.78 | 30.88 | 28.61 | 22.85 | 19.38 | |
Excise Duty | -- | -- | -- | -- | -- | |
Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
R & D Expenses | -- | -- | -- | -- | -- | |
Provisions And Contingencies | -- | -- | -- | -- | -- | |
Exp. Capitalised | -- | -- | -- | -- | -- | |
Other Expenses | 179.58 | 157.13 | 152.27 | 157.63 | 145.68 | |
P/L Before Other | 204.10 | 236.36 | 195.80 | 236.74 | 177.99 | |
Other Income | 7.74 | 9.53 | 14.89 | 14.10 | 6.18 | |
P/L Before Int. | 211.84 | 245.88 | 210.69 | 250.84 | 184.17 | |
Interest | 6.10 | 14.71 | 1.74 | 1.25 | 0.36 | |
P/L Before Exceptional Items & Tax | 205.74 | 231.17 | 208.95 | 249.59 | 183.80 | |
Exceptional Items | -- | -- | -- | -- | -- | |
P/L Before Tax | 205.74 | 231.17 | 208.95 | 249.59 | 183.80 | |
Tax | 18.52 | 20.38 | 18.18 | 23.16 | 25.82 | |
P/L After Tax from Ordinary Activities | 187.22 | 210.79 | 190.76 | 226.43 | 157.98 | |
Prior Year Adjustments | -- | -- | -- | -- | -- | |
Extra Ordinary Items | -- | -- | -- | -- | -- | |
Net Profit/(Loss) For the Period | 187.22 | 210.79 | 190.76 | 226.43 | 157.98 | |
Equity Share Capital | 13.60 | 13.60 | 13.59 | 13.59 | 13.58 | |
Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | 1,561.89 | |
Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
EPS Before Extra Ordinary | ||||||
Basic EPS | 13.77 | 15.50 | 14.03 | 16.67 | 11.64 | |
Diluted EPS | -- | 15.49 | -- | 16.66 | -- | |
EPS After Extra Ordinary | ||||||
Basic EPS. | 13.77 | 15.50 | 14.03 | 16.67 | 11.64 | |
Diluted EPS. | -- | 15.49 | -- | 16.66 | -- | |
Public Share Holding | ||||||
No Of Shares (Crores) | -- | -- | -- | -- | -- | |
Share Holding (%) | -- | -- | -- | -- | -- | |
Promoters and Promoter Group Shareholding | ||||||
a) Pledged/Encumbered | ||||||
- Number of shares (Crores) | -- | -- | -- | -- | -- | |
- Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
- Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
b) Non-encumbered | ||||||
- Number of shares (Crores). | -- | -- | -- | -- | -- | |
- Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
- Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
17.05.2023
Eris Life Standalone March 2023 Net Sales at Rs 314.58 crore, up 11.5% Y-o-Y
17.05.2023
Eris Life Consolidated March 2023 Net Sales at Rs 402.80 crore, up 31.66% Y-o-Y
20.01.2023
Eris Life Consolidated December 2022 Net Sales at Rs 423.26 crore, up 27.43% Y-o-Y
20.01.2023
Eris Life Standalone December 2022 Net Sales at Rs 332.01 crore, up 8.99% Y-o-Y
17.01.2023
Eris Lifesciences Q3 PAT seen up 7.2% YoY to Rs 1,080 cr: Nirmal Bang
08.07.2022
Eris Lifesciences Q1 PAT seen up 4.3% YoY to Rs 111.3 cr: Prabhudas Lilladher
14.04.2022
Eris Lifesciences Q4 PAT seen up 30.7% YoY to Rs 89.2 cr: Prabhudas Lilladher
13.01.2022
Eris Lifesciences Q3 PAT seen up 12.4% YoY to Rs 101.4 cr: Prabhudas Lilladher